Cytomegalovirus p65 Antibody (CMV100) - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-34595
Conjugate
Catalog #
Key Product Details
Species Reactivity
Cytomegalovirus
Applications
ELISA
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # CMV100
Format
Azide and BSA Free
Concentration
1.0 mg/ml
Product Specifications
Immunogen
Recombinant Cytomegalovirus p65 protein
Reactivity Notes
CMV
Localization
Nuclear
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Theoretical MW
65 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Description
1.0 mg/ml of antibody purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS WITHOUT BSA. Also available at 200 ug/ml WITH BSA & azide (NBP2-34332).
Antibody with azide - store at 2 to 8C.
Antibody with azide - store at 2 to 8C.
Applications for Cytomegalovirus p65 Antibody (CMV100) - Azide and BSA Free
Application
Recommended Usage
ELISA
1-5 ug/ml
Application Notes
ELISA: For coating use Ab at 1-5ug/ml, order Ab without BSA.
Optimal dilution for a specific application should be determined.
Optimal dilution for a specific application should be determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
10 mM PBS
Format
Azide and BSA Free
Preservative
No Preservative
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20 to -80C. Avoid freeze-thaw cycles.
Background: Cytomegalovirus p65
Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).
References
1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w
2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z
3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078
4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437
5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493
Alternate Names
CMV, p65
Additional Cytomegalovirus p65 Products
Product Documents for Cytomegalovirus p65 Antibody (CMV100) - Azide and BSA Free
Product Specific Notices for Cytomegalovirus p65 Antibody (CMV100) - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...